Maria Kossilos, Assoc. Chief Pharmacy Officer at Cambridge Health Alliance, joins Kristin Fox-Smith (340B ACE), Managing Director at Visante, to discuss how pharmaceutical manufacturer restrictions – some as recent as last week – put enormous financial pressure on health systems and covered entities who are doing what they can to care for vulnerable and underserved patients across America.
Kossilos and Fox-Smith describe why the 340B outlook is somewhat bleak, as the fear of continuing to lose 340B savings could well become a reality in the coming 18-24 months. However, they also describe real solutions such as utilizing 340B ESP in ways to leverage data in exchange for 340B price restoration, where possible. Fox-Smith describes Cambridge Health Alliance as the perfect case study for an organization that has figured out what works well, how to hold vendors accountable, and how to stay on top of ever-changing restrictions and requirements while restoring lost revenue without draining its internal resources.
In this episode, you will hear from two leading 340B experts who are passionate about taking care of patients – especially those that cannot afford it themselves – and advocating for the organizations on the front lines. Jim Jorgenson, Visante CEO, moderates the discussion and provides insight into the legal aspects and impact on the future of the program.